A detailed history of Savant Capital, LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Savant Capital, LLC holds 29,703 shares of CTKB stock, worth $163,366. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,703
Previous 24,133 23.08%
Holding current value
$163,366
Previous $82,000 25.61%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 04, 2025

BUY
$3.1 - $4.17 $17,267 - $23,226
5,570 Added 23.08%
29,703 $103,000
Q2 2025

Aug 06, 2025

BUY
$2.42 - $3.99 $58,401 - $96,290
24,133 New
24,133 $82,000

Others Institutions Holding CTKB

About Cytek Biosciences, Inc.


  • Ticker CTKB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 134,627,008
  • Market Cap $740M
  • Description
  • Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...
More about CTKB
Track This Portfolio

Track Savant Capital, LLC Portfolio

Follow Savant Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Savant Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Savant Capital, LLC with notifications on news.